Tetraphase Pharmaceuticals (TTPH) PT Raised to $13 at BMO Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Tetraphase Pharma (TTPH) Prices 10M Shares at $6.50/Sh
July 28, 2017 5:57 AM EDTTetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock for a public offering price of $6.50 per share. The gross... More
Stifel Upgrades Tetraphase Pharmaceuticals (TTPH) to Buy, $15 PT
July 26, 2017 6:00 AM EDTStifel upgraded Tetraphase Pharmaceuticals (NASDAQ: TTPH) from Hold to Buy with a price target of $15.00 (from $8.00) following positive results from the second Phase 3 trial of the companys lead antibiotic, eravacycline, in complicated intra-abdominal infection (cIAI).
Analyst Stephen Willey said event serves as an... More
Tetraphase Pharma (TTPH) Reports Results from Phase 3 IGNITE4 Clinical Trial in Complicated Intra-Abdominal Infections
July 25, 2017 4:29 PM EDTTetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced positive top-line results from IGNITE4, the Company's phase 3 clinical trial evaluating the efficacy and safety of twice-daily intravenous (IV) eravacycline compared to meropenem for the treatment of patients with complicated intra-abdominal infections (cIAI). The results of IGNITE4, which enrolled 500 patients, demonstrated statistical non-inferiority of eravacycline to meropenem... More
